Adaptive Biotechnologies Corporation ( ADPT ) NASDAQ Global Select

Cena: 12.08 ( 1.26% )

Aktualizacja 07-10 21:58
NASDAQ Global Select
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 709
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 68%
Ilość akcji: 144 772 992
Debiut giełdowy: 2019-06-27
WWW: https://www.adaptivebiotech.com
CEO: Mr. Chad M. Robins M.B.A.
Adres: 1165 Eastlake Avenue East
Siedziba: 98109 Seattle
ISIN: US00650F1093
Opis firmy:

Adaptive Biotechnologies Corporation, firma komercyjna, opracowuje platformę medycyny odpornościowej do diagnozy i leczenia różnych chorób. Firma oferuje Immunoseq, platformę i podstawowy produkt immunosekcji, który służy do odpowiadania na pytania badawcze, a także do odkrywania nowych sygnałów prognostycznych i diagnostycznych; i T-detect Covid do potwierdzenia poprzedniej infekcji COVID-19. Zapewnia również klonoseq, kliniczny produkt diagnostyczny do wykrywania i monitorowania minimalnej choroby resztkowej u pacjentów z szpiczakiem mnogim, ostrej białaczki limfoblastycznej komórek B oraz przewlekłą białaczkę limfocytową, a także dostępną jako test laboratoryjny w kwalifikacji CLIA opracowany dla pacjentów z innymi rakami limfatycznymi; oraz Immunoseq T-Map Covid dla programistów szczepionek i badaczy do pomiaru odpowiedzi immunologicznej komórek T na szczepionki. Ponadto firma oferuje rurociąg produktów i usług klinicznych, które są wykorzystywane do diagnozowania, monitorowania i leczenia chorób, takich jak rak, schorzenia autoimmunologiczne i choroby zakaźne. Służy badań nauk przyrodniczych, diagnostyki klinicznej i aplikacji do odkrywania leków. Adaptive Biotechnologies Corporation prowadzi strategiczną współpracę z Genentech, Inc. w celu rozwoju, produkcji i komercjalizacji terapii komórek T ukierunkowanych na neoantygen do leczenia szeregu nowotworów; oraz Microsoft Corporation w celu opracowania testów diagnostycznych wczesnego wykrywania różnych chorób z jednego badania krwi. Firma była wcześniej znana jako Adaptive TCR Corporation i zmieniła nazwę na Adaptive Biotechnologies Corporation w grudniu 2011 roku. Adaptive Biotechnologies Corporation został zarejestrowany w 2009 roku i ma siedzibę w Seattle w stanie Waszyngton.

Wskaźniki finansowe
Kapitalizacja (USD) 1 835 157 360
Aktywa: 558 506 000
Cena: 12.08
Wskaźnik Altman Z-Score: -1.8
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -12.7
Ilość akcji w obrocie: 68%
Średni wolumen: 2 219 256
Ilość akcji 151 917 000
Wskaźniki finansowe
Przychody TTM 177 282 000
Zobowiązania: 334 932 000
Przedział 52 tyg.: 3.51 - 12.43
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -0.9
P/E branży: 26.1
Beta: 1.447
Raport okresowy: 2025-07-31
WWW: https://www.adaptivebiotech.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Julie Rubinstein President & Chief Operating Officer 721 040 1972
Dr. Harlan S. Robins Ph.D. Co-Founder & Chief Scientific Officer 711 094 1973
Dr. Sharon Benzeno Ph.D. Chief Commercial Officer of Immune Medicine 630 722 1974
Mr. Kyle Piskel Vice President, Chief Financial Officer & Principal Accounting Officer 375 905 1984
Mr. Chad M. Robins M.B.A. Co-Founder, Chief Executive Officer & Chairman 1 003 556 1975
Mr. Francis T. Lo Chief People Officer 0 1981
Ms. Susan Bobulsky Chief Commercial Officer of MRD 0 1981
Karina Calzadilla Vice President of Investor Relations 0 0
Ms. Stacy L. Taylor Senior Vice President, General Counsel & Corporate Secretary 0 1960
Mr. Christopher Carlson Ph.D. Founder 0 0
Wiadomości dla Adaptive Biotechnologies Corporation
Tytuł Treść Źródło Aktualizacja Link
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com 2025-05-09 17:05:49 Czytaj oryginał (ang.)
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect? The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2025-05-08 15:02:16 Czytaj oryginał (ang.)
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year. zacks.com 2025-05-08 14:45:55 Czytaj oryginał (ang.)
Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chief Executive Officer & Co-Founder Kyle Piskel - Chief Financial Officer Susan Bobulsky - Chief Commercial Officer Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Yuko Oku - Morgan Stanley Sebastian Sandler - JPMorgan Tom Stevens - TD Cowen Corey Rosenbaum - Scotia Bank Maggie Boeye - William Blair Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2025 Earnings Conference Call. seekingalpha.com 2025-05-02 01:46:51 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-05-02 00:05:41 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. zacks.com 2025-05-01 22:40:53 Czytaj oryginał (ang.)
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. “We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. globenewswire.com 2025-05-01 20:05:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com 2025-04-10 20:05:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission globenewswire.com 2025-04-08 12:00:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma Enhanced assay granted approval by New York State's Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) --  Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity. globenewswire.com 2025-03-11 10:00:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2025-02-12 15:01:17 Czytaj oryginał (ang.)
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year. zacks.com 2025-02-12 12:40:15 Czytaj oryginał (ang.)
Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Sharon Benzeno - Chief Commercial Officer of Immune Medicine Harlan Robins - Co-Founder & Chief Scientific Officer Conference Call Participants Andrew Brackmann - William Blair Rachel Vatnsdal - JPMorgan Mark Massaro - BTIG Sung Ji Nam - Scotiabank Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Fourth Quarter and Full Year 2024 Financial Results Conference Call. seekingalpha.com 2025-02-11 21:47:05 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-02-11 21:31:11 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago. zacks.com 2025-02-11 20:36:07 Czytaj oryginał (ang.)
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com 2025-02-11 18:05:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. globenewswire.com 2025-02-05 18:05:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 11, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com 2025-01-22 18:05:00 Czytaj oryginał (ang.)
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? Here is how Adaptive Biotechnologies (ADPT) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year. zacks.com 2025-01-17 12:41:24 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock? Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com 2025-01-16 11:35:46 Czytaj oryginał (ang.)
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum globenewswire.com 2025-01-14 09:30:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025 SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today that the new Medicare Clinical Laboratory Fee Schedule (CLFS) rate for its next-generation sequencing (NGS)-based clonoSEQ® test for minimal – or measurable – residual disease (MRD) assessment is now in effect as of January 1, 2025. The CLFS rate for clonoSEQ (PLA 0364U) was set at $2,007, consistent with the final gapfill rate recommendation for the test. globenewswire.com 2025-01-07 09:30:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. globenewswire.com 2025-01-02 18:05:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL globenewswire.com 2024-12-07 20:30:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2024, in San Diego. Among these abstracts are a plenary session presentation, a late-breaking abstract and 25 other oral presentations. globenewswire.com 2024-12-03 09:30:00 Czytaj oryginał (ang.)
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year. zacks.com 2024-11-29 12:40:29 Czytaj oryginał (ang.)
Adaptive Biotechnologies: Making Some Progress Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driven by clonoSEQ, continues to show significant growth, and the company's balance sheet remains strong. An updated analysis around Adaptive Biotechnologies follows in the paragraphs below. seekingalpha.com 2024-11-26 12:53:00 Czytaj oryginał (ang.)
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know The consensus price target hints at a 31.4% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-11-15 13:00:40 Czytaj oryginał (ang.)
Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head of IR Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Matt Sykes - Goldman Sachs Maggie Boeye - William Blair Corey Rosenbaum - Scotiabank Operator Good day, and welcome to Adaptive Biotechnologies Third Quarter Financial Results [Operator Instructions]. As a reminder, this call may be recorded. seekingalpha.com 2024-11-07 23:57:07 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2024-11-07 21:30:47 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.35 per share a year ago. zacks.com 2024-11-07 21:15:36 Czytaj oryginał (ang.)
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostics Services Program (MolDX), has expanded coverage of clonoSEQ® to include detection and monitoring of measurable residual disease (MRD) in Medicare patients with mantle cell lymphoma (MCL). MCL is a sub-type of non-Hodgkin lymphoma (NHL) with an annual incidence of approximately 4,000 cases per year in the United States.1 It is an aggressive disease, and most patients will relapse repeatedly; some shortly after frontline therapy, while others as late as 15 years after initial remission.2 , 3 Given this challenging and variable course of disease, it is critical to effectively assess depth of response in patients undergoing treatment and monitor for recurrence or disease progression following remission. globenewswire.com 2024-11-07 09:30:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com 2024-10-09 20:05:00 Czytaj oryginał (ang.)
Adaptive Announces IVDR Certification for clonoSEQ® in European Union clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies globenewswire.com 2024-08-29 11:30:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. globenewswire.com 2024-08-22 20:03:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Karina Calzadilla – Head-Investor Relations Chad Robins – Chief Executive Officer and Co-Founder Kyle Piskel – Chief Financial Officer Susan Bobulsky – Chief Commercial Officer-MRD Conference Call Participants Mark Massaro – BTIG David Westenberg – Piper Sandler Tejas Savant – Morgan Stanley Dan Brennan – TD Cowen Andrew Brackmann – William Blair Rachel Vatnsdal – JPMorgan Sung Ji Nam – Scotiabank Operator Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2024 Earnings Call. seekingalpha.com 2024-08-02 02:25:25 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-08-02 00:00:28 Czytaj oryginał (ang.)
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago. zacks.com 2024-08-01 23:20:25 Czytaj oryginał (ang.)
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024. globenewswire.com 2024-08-01 20:05:00 Czytaj oryginał (ang.)
3 Precision Medicine Stocks Tailoring Treatments Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant. investorplace.com 2024-07-21 10:00:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024 SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com 2024-07-11 20:05:00 Czytaj oryginał (ang.)
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers globenewswire.com 2024-05-31 11:30:00 Czytaj oryginał (ang.)